Myriad Genetics (MYGN) investor relations material

Leadership insights and management philosophy

• CEO and board members demonstrated confidence by purchasing shares, reflecting personal conviction in the company's direction.

• CEO's first year emphasized customer trust, product quality, and the need for innovation and updated strategy.

• Leadership team expanded with experienced hires to drive growth in MRD and molecular teams.

• CFO highlighted a shift to a culture of execution excellence, focusing on process discipline and organizational efficiency.

Strategic priorities and growth outlook

• Three main priorities: deliver on commitments, achieve financial targets, and instill execution excellence.

• Guidance for $870 million at midpoint assumes mid-single-digit sequential growth each quarter after Q1.

• Expanded hereditary cancer panels and bifurcation of women's health sales channels expected to drive growth.

• GeneSight and prenatal segments targeted for mid-single-digit growth, with new product launches like FirstGene in Q3.

Operational improvements and sales strategy

• Reorganization from business unit to functional structure freed up $35 million for efficiency and sales effectiveness.

• Sales force optimization and targeted tools are expected to enhance focus and drive volume, especially in hereditary cancer and GeneSight.

• Double-digit growth achieved in both affected and unaffected hereditary cancer segments in Q4.